Myocardial Oxygen Consumption in Patients with Idiopathic Dilated Cardiomyopathy: Effects of Vasodilating and Inotropic Agents

  • Ch. Holubarsch
  • G. Hasenfuss
  • H. Just
Conference paper

Abstract

Idiopathic dilated cardiomyopathy is a myocardial disease of unknown origin. Several causal factors are discussed. One hypothesis involves energy depriviation in the failing myocardium, and a number of arguments exist for such an energy-starving situation [22, 23]. These include the following: (a) In some studies investigating the energy state of hypertrophied and failing myocardium, a reduced content of high energy phosphates was reported [5, 39]. However, these findings were not confirmed by others [33, 34]. (b) In the failing human myocardium, a reduction in myofibrillar ATPase activity [1, 25, 30] and a shift of the isoenzyme pattern of lactate dehydrogenase [36] has been observed. Both changes may be interpreted in terms of adaptation to energy depletion; reduced myofibrillar ATPase activity is associated with more economical tension development, as shown in mammalian myocardium [2, 15, 16] and in human myocardium [14], and the shifts in the isoforms of the lactate dehydrogenase are indicators of anaerobic glycolysis [36]. (c) A reduction in capillary density may lead to increased diffusion distances [4]. (d) A reduced ratio of mitochondria and myofibrillar volumes indicates a mismatch between the number of ATP synthesizing sites and the number of ATP consuming sites [4, 31]. (e) Reduced coronary reserve has been observed in patients with dilated cardiomyopathy using the dipyridamole test [28, 29, 32].

Keywords

Angiotensin Cardiomyopathy Catecholamine Cardiol Pyrimidin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alpert NR, Gordon MS (1962) Myofibrillar adenosine triphosphatase activity in congestive heart failure. Am J Physiol 202:940–946PubMedGoogle Scholar
  2. 2.
    Alpert NR, Mulieri LA (1982) Increasing myothermal economy of isometric force genera- tion in compensated cardiac hypertrophy induced by pulmonary artery constriction in rabbit. A characterization of heat liberation in normal and hypertrophied papillary muscle. Circ Res 50:491–500PubMedGoogle Scholar
  3. 3.
    Amin DK, Shah PK, Hulse S, Shellock FG, Swan HJC (1984) Myocardial metabolic and hemodynamic effects of intravenous MDL 17043, a new cardiotonic drug in patients with severe heart failure. Am Heart J 108:1285–1292PubMedCrossRefGoogle Scholar
  4. 4.
    Anversa P, Olivetti C, Melissari M, Loud AV (1980) Stereological measurement of cellular and subcellular hypertrophy and hyperplasia in the papillary muscle of the adult rat. J Moll Cell Cardiol 12:781–795CrossRefGoogle Scholar
  5. 5.
    Bashore TM, Magorien DJ, Letterio J, Shaffer P, Unverferth DV (1987) Histologic and biochemical correlates of the left ventricular chamber dynamics in man. J Am Coll Cardiol 9:734–742PubMedCrossRefGoogle Scholar
  6. 6.
    Braunwald E (1971) Control of myocardial oxygen consumption: physiologic and clinical considerations. Am J Cardiol 27:416–432PubMedCrossRefGoogle Scholar
  7. 7.
    Cohn JN, Archibald DG, Ziesche S et al. (1986) Effects of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314:1547–1552PubMedCrossRefGoogle Scholar
  8. 8.
    CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429–1435CrossRefGoogle Scholar
  9. 9.
    Dies F, Krell MJ, Whitlow P, Liang C-S, Goldenberg I, Applefeld MM, Gilbert EM (1986) Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation 74 [Suppl II]:152Google Scholar
  10. 10.
    Dubiel IS, Dubiel IP, Frendo J, Zmudka K, Horzela T (1986) Coronary circulation and myocardial metabolism in dilated cardiomyopathy. Cor Vasa 28:356–364PubMedGoogle Scholar
  11. 11.
    Graham TP, Covell JW, Sonnenblick EH, Ross J Jr, Braunwald E (1968) Control of myocardial oxygen consumption: relative influence of contractile state and tension development. J Clin Invest 47:375–385PubMedCrossRefGoogle Scholar
  12. 12.
    Hasenfuss G, Holubarsch C, Heiss HW, Bonzel T, Funfack M, Revenaugh M, Meinertz T, Just H (1987) Hemodynamics and myocardial oxygen metabolism of pulsus alternans in patients with dilated cardiomyopathy. Clin Cardiol 10:223–327Google Scholar
  13. 13.
    Hasenfuss G, Holubarsch C, Heiss HW, Meinertz T, Bonzel T, Wais U, Lehmann M, Just H (1989) Myocardial energetics in patients with dilative cardiomyopathy. Influence of nitroprusside and enoximone. Circulation 80:51–64PubMedCrossRefGoogle Scholar
  14. 14.
    Hasenfuss G, Mulieri LA, Blanchard EM, Holubarsch C, Leavitt BJ, Ittleman F, Alpert NR (1991) Energetics of isometric force development in control and volume-overload human myocardium. Comparison with animal species. Circ Res 68:836–846PubMedGoogle Scholar
  15. 15.
    Holubarsch C, Goulette RP, Mulieri LA, Alpert NR (1983) Heat liberation in experimentally induced tetanic contractions of myocardium from normal and Goldblatt rats. In: Jacob R (ed) Cardiac adaptation of hemodynamic overload, training and stress. Steinkopff, Darmstadt, pp 158–166Google Scholar
  16. 16.
    Holubarsch C, Litten RZ, Mulieri LA, Alpert NR (1985) Energetic changes of myocardium as an adaptation to chronic hemodynamic overload and thyroid gland activity. Basic Res Cardiol 80:582–593PubMedCrossRefGoogle Scholar
  17. 17.
    Holubarsch C, Hasenfuss G, Heiss HW, Meinertz T, Just H (1987) Acute and chronic changes of myocardial energetics in the mammalian and human heart. Basic Res Cardiol 82 [Suppl II]:377–388PubMedGoogle Scholar
  18. 18.
    Holubarsch C, Hasenfuss G, Just H, Blanchard E, Mulieri LA, Alpert NR (1989) Influence of the positive inotropic substance pimobendane (UDCG 115 BS) on contractile economy of guinea pig papillary muscles. J Cardiovasc Pharmacol 14 [Suppl 2]:S13-S17PubMedGoogle Scholar
  19. 19.
    Holubarsch C, Hasenfuss G, Blanchard E, Mulieri LA, Alpert NR (1989) Influence of the phosphodiesterase inhibitor E-1020 on mechanics and energetics in guinea pig papillary muscles. Circulation 80 [Suppl II]:612Google Scholar
  20. 20.
    Holubarsch C, Hasenfuss G, Just H, Blanchard EM, Mulieri LA, Alpert NR (1990) Modulation of myothermal economy of isometric force generation by positive inotropic interventions in the guinea pig myocardium. Cardioscience 1:33–41PubMedGoogle Scholar
  21. 21.
    Holubarsch Ch, Hasenfuss G, Thiefelder L, Just H (1991) Energetic consequences of substances currently used or recommended for long-term treatment of chronic heart failure. Bas Res Cardiol 86, Suppl I:107–112Google Scholar
  22. 22.
    Katz AM (1986) Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 73 [Suppl III]: 184–188Google Scholar
  23. 23.
    Katz AM (1989) Energy requirements of contraction and relaxation: implications for inotropic stimulation of the failing heart. Basic Res Cardiol 84 [Suppl I]:47–53PubMedCrossRefGoogle Scholar
  24. 24.
    Laskey WK, Reichek N, Sutton MS, Untereker WJ, Hirshfeld JW (1983) Myocardial oxygen consumption in left ventricular hypertrophy and its relation to left ventricular mechanics. Am J Cardiol 52:852–858PubMedCrossRefGoogle Scholar
  25. 25.
    Leclerque JF, Swynghedauw B (1976) Myofibrillar ATPase, DNA and hydroxyproline content of human hypertrophied heart. Eur J Clin Invest 6:27–33CrossRefGoogle Scholar
  26. 26.
    Martin JL, Likoff MJ, Janicki JS, Laskey WK, Hirshfeld JW, Weber KT (1984) Myocardial energetics and clinical response to the cardiotonic agent MDL 17043 in advanced heart failure. J Am Coll Cardiol 4:875–883PubMedCrossRefGoogle Scholar
  27. 27.
    Mirsky I (1979) Elastic properties of the myocardium: a quantitative approach with physiological and clinical applications. In: Berne RM (ed) Handbook of physiology. The cardiovascular system. American Physiological Society, Washington, pp 497–531Google Scholar
  28. 28.
    Nitenberg A, Foult IM, Blanchet F, Zonioneche S (1985) Multifactorial determinants of reduced coronary flow reserve after dipyridanole in dilated cardiomyopathy. Am J Cardiol 55:748–754PubMedCrossRefGoogle Scholar
  29. 29.
    Opherk D, Schwarz F, Mall G, Manthey J, Baller D, Kuebler W (1983) Coronary dilator capacity in idiopathic dilated cardiomyopathy: analysis of 16 patients. Am J Cardiol 51:1657–1662PubMedCrossRefGoogle Scholar
  30. 30.
    Pagani ED, Alousi AA, Grant AM, Order TM, Dziuban SW, Allen PD (1988) Changes in myofibrillar content and Mg-ATPase activity in ventricular tissue from patients with heart failure caused by coronary artery disease, cardiomyopathy, or mitral valve insufficiency. Circ Res 63:380–385PubMedGoogle Scholar
  31. 31.
    Page E, McCalister LP (1973) Quantitative electron microscopic description of heart muscle cells. Application to normal, hypertrophied, and thyroxin-stimulated heart. Am J Cardiol 31:172–181PubMedCrossRefGoogle Scholar
  32. 32.
    Pasternac A, Noble J, Streulens Y, Elie R, Heuschke C, Bourassa MG (1982) Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries. Circulation 65:778–789PubMedCrossRefGoogle Scholar
  33. 33.
    Regitz V, Rappolder M, Bossaller C, Strasser R, Fleck E (1990) Myocardial ATP, ADP and AMP in heart failure of different origins. Eur Heart J 11[Suppl]:189Google Scholar
  34. 34.
    Regitz V, Fleck E (1992) Adenine nucleotide metabolism and contracile dysfunction in heart failure. Basic Res Cardiol 87, Suppl I:321–329PubMedGoogle Scholar
  35. 35.
    Rooke GA, Feigl EO (1982) Work as a correlate of canine left ventricular oxygen consumption, and the problem of catecholamine oxygen wasting. Circ Res 50:273–286PubMedGoogle Scholar
  36. 36.
    Schultheiss HP (1990) Effect on the myocardial energy metabolism of angiotensin- converting enzyme inhibition in chronic heart failure. Am J Cardiol 65:G74-G81CrossRefGoogle Scholar
  37. 37.
    SOLVD investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection farctions and congestive heart failure. N Engl J Med 325:293–302Google Scholar
  38. 38.
    Strauer BE (1979) Ventricular function and coronary hemodynamics in hypertensive heart disease. Am J Cardiol 44:999–1006PubMedCrossRefGoogle Scholar
  39. 39.
    Swain JL, Sabina RL, Peyton RB et al. (1979) Derangements in myocardial purin and pyrimidin metabolism in patients with coronary artery disease and left ventricular hypertrophy. Proc Natl Acad Sci USA 79:655–659CrossRefGoogle Scholar
  40. 40.
    Thierfelder L, Holubarsch C, Hasenfuss G, Heiss HW, Just H (1991) The effect of the partial beta-1-adrenoceptor agonist xamoterol on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol 17:593–599PubMedCrossRefGoogle Scholar
  41. 41.
    von Herrath M, Hasenfuss G, Holubarsch C, Hofmann T, Heiss HW, Just H (1990) Repeated determination of left ventricular wall thickness from mass and volume during one cardiac cycle for the calculation of left ventricular wall stress parameters. Clin Cardiol 13:218–220CrossRefGoogle Scholar
  42. 42.
    Viquerat CE, Kereiakes D, Morris L, Daly PA, Wexman M, Frank P, Parmley WW, Chatterjee K (1985) Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17043, a new inotropic vasodilator agent, in patients with severe heart failure. J Am Coll Cardiol 5:326–332PubMedCrossRefGoogle Scholar
  43. 43.
    Xamoterol in Severe Heart Failure Study Group (1990) Xamoterol in severe heart failure. Lancet 336:1–6CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • Ch. Holubarsch
    • 1
  • G. Hasenfuss
    • 1
  • H. Just
    • 1
  1. 1.Department of Cardiology, Internal MedicineUniversity of FreiburgFreiburgFed. Rep. of Germany

Personalised recommendations